SCHEMBL6011683

SCHEMBL6011683

CC(SC(C)c1cccc(N2CCCC2)c1)c1cccc(N2CCCC2)c1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PRMT6 Q96LA8 1/20 0.44
ALDH1A1 P00352 4/20 0.44
KDM4E B2RXH2 2/20 0.44
MEN1 O00255 2/20 0.44
KMT2A Q03164 2/20 0.44
HSD17B10 Q99714 2/20 0.44
GAA P10253 1/20 0.44
HPGD P15428 1/20 0.44
AGXT P21549 1/20 0.41
NOTUM Q6P988 1/20 0.40
APP P05067 1/20 0.40
MAPT P10636 2/20 0.39
ADRA2C P18825 1/20 0.39
CACNA2D1 P54289 1/20 0.38
L3MBTL1 Q9Y468 2/20 0.38
GFER P55789 1/20 0.38
HRH3 Q9Y5N1 1/20 0.38
ADRB1 P08588 1/20 0.38
FFAR1 O14842 1/20 0.37
ALOX15 P16050 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26452390 0.85 PRMT6 (0.44) PRMT6ALDH1A1KDM4EMEN1KMT2A
SCHEMBL3534359 0.84 NOTUM (0.54) PRMT6ALDH1A1KDM4EMEN1KMT2A
SCHEMBL4547919 0.82 NOTUM (0.52) PRMT6ALDH1A1KDM4EMEN1KMT2A
SCHEMBL9839870 0.82 PRMT6 (0.44) PRMT6ALDH1A1KDM4EMEN1KMT2A
SCHEMBL14349225 0.80 NOTUM (0.54) PRMT6ALDH1A1KDM4EMEN1KMT2A
SCHEMBL25524602 0.77 PRMT6 (0.49) PRMT6ALDH1A1KDM4EMEN1KMT2A
SCHEMBL16019525 0.76 NOTUM (0.56) ALDH1A1KDM4ENOTUMMAPTADRA2C
SCHEMBL27526756 0.76 PRMT6 (0.44) PRMT6ALDH1A1KDM4EMEN1KMT2A
SCHEMBL5791930 0.74 PRMT6 (0.47) PRMT6ALDH1A1KDM4EMEN1KMT2A
Hydrochloric Acid SCHEMBL17871901 0.73 KMT2A (0.45) PRMT6ALDH1A1KDM4EMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060270649-A1 AZETIDINE DERIVATIVES, THEIR PREPARATION AND MEDICAMENTS CONTAINING THEM AVENTIS PHARMA S.A. (FR) 2006-11-30 US disclosed
US-6858603-B2 Acetindine derivatives, their preparation and medicaments containing them AVENTIS PHARMA S.A. (FR) 2005-02-22 US disclosed
US-20040235816-A1 Azetidine derivatives, their preparation and medicaments containing them AVENTIS PHARMA S.A. (FR) 2004-11-25 US disclosed
US-20030162808-A1 Acetindine derivatives, their preparation and medicaments containing them AVENTIS PHARMA S.A. (FR) 2003-08-28 US disclosed
US-6518264-B2 For treatment/prevention of psychoses, other brain disorders, and cardiovascular disorders AVENTIS PHARMA S.A. (FR) 2003-02-11 US disclosed
US-20020035102-A1 Azetidine derivatives, their preparation and medicaments containing them AVENTIS PHARMA S.A. (FR) 2002-03-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040235816-A1 Azetidine derivatives, their preparation and medicaments containing them AZI2, ADRA2A, ADRA2C PRMT6 4063/4885ALDH1A1 186/4885KDM4E 2212/4885
US-20060270649-A1 AZETIDINE DERIVATIVES, THEIR PREPARATION AND MEDICAMENTS CONTAINING THEM AZI2, QDPR, ADRA2A PRMT6 3995/4885ALDH1A1 303/4885KDM4E 2165/4885
US-20020035102-A1 Azetidine derivatives, their preparation and medicaments containing them CYP11B2, AZI2, CYP2C19 PRMT6 453/4885ALDH1A1 639/4885KDM4E 408/4885
US-20030162808-A1 Acetindine derivatives, their preparation and medicaments containing them ADRA1D, ADRB2, AZI2 PRMT6 4617/4885ALDH1A1 32/4885KDM4E 4055/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.